|
Post by kc on Jun 3, 2017 16:06:44 GMT -5
I think that's Dr Edelmann standing next to Rick, isn't it? Yes that is Dr. Edelman. Amazing teacher and diabetes advocate.
|
|
|
Post by kc on Jun 2, 2017 11:19:48 GMT -5
When they are selling it wholesale to the Brazilian company we don't have to worry about anything more than supplying the Afrezza. Drugs sold in other countries are sometimes 90% cheaper than the USA. You want to get the Afrezza moving you need to sign a few deals like this one for supplying the product. Universal Health Care country then it might sell very cheap on the wholesale side but builds up production and that is good for MannKind long term.
Brazil has a problem. Poor country lots of diabetes cases to treat. Afrezza is the perfect product to help an entire nation with limited numbers of Doctors, Hospitals and treatment facilities help their patients. Again Telemed with Afrezza and titration will prove the story about early treatment with Afrezza will save lives and complications that cost a Gov Universal plan big treatment dollars from Diabetes complications.
|
|
|
Post by kc on Jun 1, 2017 17:33:34 GMT -5
I think there is no Amgen connection at all; they are going it alone this time. Matt believed in focusing only on the USA market, whereas now Mike is taking a global approach including the MOU with OneDrop. The Street did not trust Matt and the share price collapsed accordingly. The Street dropped analyst coverage altogether. Matt was never a confident presenter, Mike is. He has the winner mentality. For me this is a long-term retirement investment ... I can wait I personally like Matt. But agree with you that the Analyst and the Street don't like anything to do with the old MannKind image. I think that over the last 16 months Matt has done the Job very well as we would not have Mike and his team had it not been for the work that Matt did in bringing on the next generation of MannKind leaders. So give Matt the credit he is due.
The board must have planned this out as its timing seems to make it suspect of a changing of the guard. They wanted to continuity of having Matt on board for the Shareholders meeting and for the 1st qtr call. Thinking back when on that 1st qtr call they didn't take any questions but had a few from Shareholders. It was evident that MannKind is not even followed by any analyst at this point. Written off for dead. The board knew this and had to make a change as a true living / breathing company has more open and transparent visibility that Matt was not comfortable with being that type of leader. Lets face it CFO bean counters are not Big PR hype type folks.
The 2nd indication something was up was they didn't take any questions at the shareholders meeting. that is very odd. Was that a tip off to Matt's departure? I would not think so but it is a signal that some thing is up. Good or bad there is something going on behind the scenes.
Frankly I have not had the confidence in the Board as they don't seem invested in the company. I don't know the amount of stock they own but when it comes to insider ownership we are on the poor side as there is not much owned by Management or the board of directors. That should be a tip off to all of us regarding management engagement. Al & Hakan had the most shares. nobody else including Matt had many shares.
Let's hope the worst is behind us and that something positive is ahead shareholders.
|
|
|
Post by kc on Jun 1, 2017 17:15:08 GMT -5
Leanne, Its heart breaking. I'm so sorry to hear about him.
|
|
|
Post by kc on Jun 1, 2017 3:20:52 GMT -5
Sorry, but if the BOD and execs were as excruciatingly bad as you say then something went badly wrong with your due diligence that you missed that. If AMGEN have to pay $78 per share for Mannkind I think that puts an abrupt end to the AMGEN rumors. If Nate Pile is correct $78 pps in a year may look like a bargain. If what Dr Bruce Bode said a few weeks back at the Medscape educational session about all T2s being put on afrezza within a year or two of diagnosis becomes 20% real, $200 pps is a bargain. Every time I see TCOYD and Edelman afrezza is always hanging around and the last I checked Edelman is the architect of the Onduo protocol. What's Piles 3 yr target, $400? If MNKD signs a few more international deals before July there will be more than Amgen interested. China may be more real than not and so does the middle east. Dr. Edelman Will be in Overland Park Kansas on Saturday with us TCOYD diabetes program. Mannkind Will also be there exhibiting.
|
|
|
Post by kc on Jun 1, 2017 2:52:37 GMT -5
The stock is lightly traded in Tel Aviv this morning
|
|
|
Post by kc on May 31, 2017 21:48:30 GMT -5
What is especially exciting about this deal is that, unlike MannKind here in the USA, Biomm is known and has been respected by the Brazilian medical community for 40+ years. Because Biomm is so well known and were the #1 insulin manufacturer & distributor in Brazil (#4 globally) once they launch Afrezza, I believe you will see very rapid sales growth. They won't face the obstacles MannKind has had to overcome. Great choice, MannKind! Brazil is universal healthcare. But they lack doctors and hospitals. They have 191 million citizens. They need medicines that provide early intervention treatment. That is something Afrezza offers. Early treatment of diabetes reduce cost and complications for their universal healthcare system. MannKind has plenty capacity at their factory in Danbury so they can sell it cheap especially if I have tremendous adoption rate in Brazil. This deal is not about every positional factories in other countries. It's about selling Afrezza. Doctors in countries like Brazil will adept based on the studies that have been produced especially the studies that were presented at the 2016 ADA convention. I would bet that there will be quicker adaption for under 18 years old.
|
|
|
Post by kc on May 31, 2017 19:57:19 GMT -5
The company's financials are listed on their webpage unfortunately they're published in Portuguese. So it's impossible to read a know what size company we are dealing with. But at some point in time they were one of the fourth or fifth largest insulin producers in the world. So the company does have some critical mass. 12, million diabetics waiting for Afrezza. Okay, so first, sorry I do not know how to make this simple for any/everyone here. - You can download financials here - ri.biomm.com/conteudo_pt.asp?idioma=0&conta=28&tipo=57017
- Go to translate.google.com/ and click the link under the box to "translate a document"
- Click "Choose File" and select the file you saved/downloaded
- Change drop down from "Detect language" to "Portuguese"
- Verify you have "English" selected on the right (if that is what you speak/read)
You will still have to do a currency conversion, but the financial looks much more readable.
Edit: and then after posting this, I see mnkdfann perhaps has a better mousetrap here - mnkd.proboards.com/post/109403
Yes I know about Google translate I was just too lazy to do it and wanted to go home for the day from the office
|
|
|
Post by kc on May 31, 2017 19:56:01 GMT -5
You gotta think part of making a deal like this where a company is going to invest a lot of time and money to set up distribution of Afrezza in another country that they were assured Afrezza will be available when it's required . Weather it's 9 months or not there is a plan in place where we will be able to sell Afrezza at the date and time needed. Rest assured big companies don't make deals like this if they think the company they are dealing with will be bankrupt. So. I don't care what any naysayers say Afrezza and MannKind is here to stay and will be a huge success. Congrats to all the hard working people at MNKD. Well done.. Perhaps BIOMM has also been buying shares? Their financials are in Portuguese so I can't read to determine what the financial strength of that company might be. .
|
|
|
Post by kc on May 31, 2017 19:30:21 GMT -5
You gotta think part of making a deal like this where a company is going to invest a lot of time and money to set up distribution of Afrezza in another country that they were assured Afrezza will be available when it's required . Weather it's 9 months or not there is a plan in place where we will be able to sell Afrezza at the date and time needed. Rest assured big companies don't make deals like this if they think the company they are dealing with will be bankrupt. So. I don't care what any naysayers say Afrezza and MannKind is here to stay and will be a huge success. Congrats to all the hard working people at MNKD. Well done.. The company's financials are listed on their webpage unfortunately they're published in Portuguese. So it's impossible to read a know what size company we are dealing with. But at some point in time they were one of the fourth or fifth largest insulin producers in the world. So the company does have some critical mass. 12, million diabetics waiting for Afrezza.
|
|
|
Post by kc on May 31, 2017 19:28:14 GMT -5
This link also says the approval process takes about 9 months. I wonder if the approval process is already underway? The one thing that someone else already mentioned is that the distributor will be responsible for pricing. I hope they price it competitively, unlike SNY. Will MNKD just be the manufacturer/wholesaler and sell at a fixed (volume based) price? Very encouraging announcement and hope there are many more to come shortly. 9 months? Is that with or without fast-track? www.jmcinc.net/brazil-oks-fast-track-assessment-for-device-and-pharma-trial-applications/Brazil OKs fast-track assessment for device and pharma trial applications by JMC on July 6, 2012 Brazil’s regulatory agency, Anvisa, has announced that proposals to fast-track the licensing-assessment of a large proportion of applications for clinical trials of drugs and medical devices have received approved1. Pending the formal publication of the enacted resolution by Anvisa and the precise detail of the policy, the government has issued a statement confirming that applications involving trials already approved in the EU, US, Japan, Australia or Canada will be fast-tracked, said Anvisa… The partner may already have it approved since diabetes is it epidemic proportions in Brazil. BIOMM is a known insulin producer in the country. It's their business. I bet you they get this fast tracked if not handled already.
|
|
|
Post by kc on May 31, 2017 18:41:37 GMT -5
Job well done by MannKind Management team. They made a real deal with a big player in the Brazil marketplace.
|
|
|
Post by kc on May 31, 2017 16:24:38 GMT -5
MannKind will be there with a Tradeshow booth and I know their local regional rep will be there and so will the Cynthia Rogers Celt who posted her Twitter announcement. Anthony "Duck Fiabetes" will also be at the event.
|
|
|
Post by kc on May 31, 2017 12:10:42 GMT -5
This Saturday MannKind will be at the Overland Park, Kansas Convention Center with the folks from TCOYD.
Taking Control of Your Diabetes” Health Fair In Kansas
With Dr. Steven Edelman and Jeremy Pettus
www.tcoyd.org/conference-health-fair/detail/overland-park-ks-2017-06-03/
If you live near Overland Park, Kansas, you’ll want to check out the upcoming “Taking Control of Your Diabetes Conference & Health Fair,” taking place on Saturday, June 3, 2017, at the Overland Park Convention Center.
Taking Control of Your Diabetes (TCOYD) is a nonprofit organization founded by Steven Edelman, an endocrinologist with Type 1 diabetes, in 1995 to “educate and motivate people with diabetes to take a more active role in their condition.” The group has a number of initiatives, including its online reality series Extreme Diabetes Makeover; its recurring video series, “The Edelman Report”; and its national conferences and health fairs.
The conventions feature lectures from well-known speakers, health screenings, the opportunity to speak with diabetes specialists, exhibits from diabetes-related companies and organizations, and a healthful banquet lunch.
The Overland Park conference has both Type 1 and Type 2 diabetes tracks. The Type 1 program includes presentations on topics such as “Treatments for Type 1 Other Than Insulin,” “Thyroid and Other Autoimmune Disease,” and “Advanced CGM and Pumping.” The Type 2 program includes presentations on topics such as “Do You Know Your ABCs: A1C, Blood Pressure, and Cholesterol,” “Lighten Up Your Plate With Chef Lewis,” and “An In-Depth Look at Type 2 Treatments, Including Insulin Options.”
The registration fee is $30 per person ($25 per person for two or more registering together) through 12 PM PST on May 24. After May 24 and onsite, the registration fee is $45 per person. To register, call (800) 998-2693 or visit www.tcoyd.org.
Financial aid is available for people in need. For more information, call TCOYD at (800) 998-2693.
Health fairs will be running throughout the year at various locations in the United States. To find out when a TCOYD event will be in your area, click here to see the schedule of events for 2017.
Dr. Steven Edelman -- Afrezza Video--- www.youtube.com/watch?v=Ih3ZaRjtPOs
|
|
|
Post by kc on May 30, 2017 15:23:26 GMT -5
My bad... It is an requesting an extension of a previous grant of confidential treatment
www.sec.gov/Archives/edgar/data/318154/999999999717006565/filename1.pdf
Amgen Inc. File No. 0-12477 - CF#35032 _____________________ Amgen Inc. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on May 8, 2012 and Form 10-K filed on February 19, 2015. Based on representations by Amgen Inc. that this information qualifies as confidential trade secrets, commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified: Exhibit to Form Filed on Confidential Treatment Granted 10.37 10-K February 19, 2015 through May 8, 2022 10.55 10-Q May 8, 2012 through May 8, 2022 For the Commission, by the Division of Corporation Finance, pursuant
Mod's please delete this thread.
|
|